论文部分内容阅读
目的分析探讨前列地尔注射液治疗对2型糖尿病合并下肢血管病变的影响及对患者肱踝脉搏波速度(baPwV)、踝肱指数(ABI)、血清TNF-α浓度的影响。方法将80例患者按照随机分配的方式分为对照组与治疗组,每组各40例。对照组患者行常规治疗方法,治疗组患者在对照组治疗基础上行静脉注射前列地尔注射液10μg/d,连续给药20d,20d为一个疗程,治疗一疗程后间隔20d继续治疗。4个疗程后比对两组患者baPwV、ABI、血清TNF-α浓度变化情况。结果两组患者治疗前后baPwV、ABI、血清TNF-α浓度有明显变化,P<0.05;经过4个疗程治疗后,治疗组相比对照组的baPwV、血清TNF-α浓度有明显差异,P<0.05,具有统计学意义;ABI对比无统计学意义,P>0.05。结论前列地尔注射液能够降低2型糖尿病合并下肢血管病变患者baPwV、血清TNF-α浓度,应坚持持久治疗。血清TNF-α浓度有很大可能是糖尿病患者发生血管并发症的危险因子,应给予密切的关注。
Objective To investigate the effect of alprostadil injection on type 2 diabetes mellitus with lower extremity vascular lesions and its effects on brachial-ankle pulse wave velocity (baPwV), ankle-brachial index (ABI) and serum TNF-α levels. Methods Eighty patients were divided into control group and treatment group according to the random distribution method, 40 cases in each group. Patients in the control group underwent routine treatment. Patients in the treatment group received 10 μg / d of alprostadil intravenously for 20 days on the basis of the control group, and continued for 20 days after treatment for one course of treatment. The changes of baPwV, ABI and serum TNF-α in the two groups after 4 courses of treatment were compared. Results The concentrations of baPwV, ABI and serum TNF-α in the two groups had significant changes before and after treatment (P <0.05). After 4 courses of treatment, the concentrations of serum TNF-α in the treatment group were significantly different from those in the control group (P < 0.05, with statistical significance; ABI no significant statistical significance, P> 0.05. Conclusion Alprostadil injection can reduce the concentration of baPwV and serum TNF-α in patients with type 2 diabetes mellitus complicated with lower extremity vascular disease. Persistent treatment should be maintained. Serum TNF-α concentration is likely to be a risk factor for vascular complications in patients with diabetes should be given close attention.